<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39162531</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2379-5042</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>mSphere</Title><ISOAbbreviation>mSphere</ISOAbbreviation></Journal><ArticleTitle>Mapping disparities in viral infection rates using highly multiplexed serology.</ArticleTitle><Pagination><StartPage>e0012724</StartPage><MedlinePgn>e0012724</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00127-24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/msphere.00127-24</ELocationID><Abstract><AbstractText Label="UNLABELLED">Despite advancements in medical interventions, the disease burden caused by viral pathogens remains large and highly diverse. This burden includes the wide range of signs and symptoms associated with active viral replication as well as a variety of clinical sequelae of infection. Moreover, there is growing evidence supporting the existence of sex- and ethnicity-based health disparities linked to viral infections and their associated diseases. Despite several well-documented disparities in viral infection rates, our current understanding of virus-associated health disparities remains incomplete. This knowledge gap can be attributed, in part, to limitations of the most commonly used viral detection methodologies, which lack the breadth needed to characterize exposures across the entire virome. Additionally, virus-related health disparities are dynamic and often differ considerably through space and time. In this study, we utilize PepSeq, an approach for highly multiplexed serology, to broadly assess an individual's history of viral exposures, and we demonstrate the effectiveness of this approach for detecting infection disparities through a pilot study of 400 adults aged 30-60 in Phoenix, AZ. Using a human virome PepSeq library, we observed expected seroprevalence rates for several common viruses and detected both expected and previously undocumented differences in inferred rates of infection between our male/female and Hispanic/non-Hispanic White individuals.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Our understanding of population-level virus infection rates and associated health disparities is incomplete. In part, this is because of the high diversity of human-infecting viruses and the limited breadth and sensitivity of traditional approaches for detecting infection events. Here, we demonstrate the potential for modern, highly multiplexed antibody detection methods to greatly increase our understanding of disparities in rates of infection across subpopulations (e.g., different sexes or ethnic groups). The use of antibodies as biomarkers allows us to detect evidence of past infections over an extended period, and our approach for highly multiplexed serology (PepSeq) allows us to measure antibody responses against hundreds of viruses in an efficient and cost-effective manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Piña</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Elko</LastName><ForeName>Evan A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0001-6472-3169</Identifier><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caballero</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Valleywise Health, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metrailer</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulrow</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Valleywise Health, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quan</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Valleywise Health, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Arizona, College of Medicine, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Creighton University, School of Medicine, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordstrom</LastName><ForeName>Lora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Valleywise Health, Phoenix, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altin</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>The Translational Genomics Research Institute (TGen), Flagstaff, Arizona, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladner</LastName><ForeName>Jason T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0001-7751-4366</Identifier><AffiliationInfo><Affiliation>The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AI152172</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 MD012388</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54MD012388</GrantID><Agency>HHS | National Institutes of Health (NIH)</Agency><Country /></Grant><Grant><GrantID>U24AI152172</GrantID><Agency>HHS | National Institutes of Health (NIH)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>mSphere</MedlineTA><NlmUniqueID>101674533</NlmUniqueID><ISSNLinking>2379-5042</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054624" MajorTopicYN="N">Health Status Disparities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012698" MajorTopicYN="N">Serologic Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000083422" MajorTopicYN="N">Virome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus C</Keyword><Keyword MajorTopicYN="N">PepSeq</Keyword><Keyword MajorTopicYN="N">antibody repertoire</Keyword><Keyword MajorTopicYN="N">health disparities</Keyword><Keyword MajorTopicYN="N">hepatitis A virus</Keyword><Keyword MajorTopicYN="N">highly multiplexed serology</Keyword><Keyword MajorTopicYN="N">human adenovirus D</Keyword><Keyword MajorTopicYN="N">human herpesviruses</Keyword><Keyword MajorTopicYN="N">human immunodeficiency virus</Keyword><Keyword MajorTopicYN="N">salivirus A</Keyword><Keyword MajorTopicYN="N">virome</Keyword><Keyword MajorTopicYN="N">virus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39162531</ArticleId><ArticleId IdType="pmc">PMC11423740</ArticleId><ArticleId IdType="doi">10.1128/msphere.00127-24</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tyler KL. 2018. Acute viral encephalitis. N Engl J Med 379:557–566. doi:10.1056/NEJMra1708714</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1708714</ArticleId><ArticleId IdType="pubmed">30089069</ArticleId></ArticleIdList></Reference><Reference><Citation>Naniche D, Oldstone MB. 2000. Generalized immunosuppression: how viruses undermine the immune response. Cell Mol Life Sci 57:1399–1407. doi:10.1007/PL00000625</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00000625</ArticleId><ArticleId IdType="pmc">PMC11147041</ArticleId><ArticleId IdType="pubmed">11078019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira L. 2018. Congenital viral infection: traversing the uterine-placental interface. Annu Rev Virol 5:273–299. doi:10.1146/annurev-virology-092917-043236</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092917-043236</ArticleId><ArticleId IdType="pubmed">30048217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, Huang X, Liu R, Lan Y, Lei Y, Zeng F, Tang X, He H. 2022. Comparison of COVID-19 induced respiratory failure and typical ards: similarities and differences. Front Med (Lausanne) 9:829771. doi:10.3389/fmed.2022.829771</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.829771</ArticleId><ArticleId IdType="pmc">PMC9196311</ArticleId><ArticleId IdType="pubmed">35712114</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahrizaila N, Lehmann HC, Kuwabara S. 2021. Guillain-Barré syndrome. Lancet 397:1214–1228. doi:10.1016/S0140-6736(21)00517-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00517-1</ArticleId><ArticleId IdType="pubmed">33647239</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger JW, Kleinman LC, Heidemann SM, Martin AA, et al. . 2020. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 383:334–346. doi:10.1056/NEJMoa2021680</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021680</ArticleId><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, et al. . 2021. Attributes and predictors of long COVID. Nat Med 27:626–631. doi:10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin NH, Campbell AJP, Zerr DM, Melvin AJ. 2011. Chapter 95, Life-threatening viral diseases and their treatment, p 1324–1335. In Fuhrman BP, Zimmerman JJ (ed), Pediatric critical care, 4th ed. Mosby, Saint Louis.</Citation></Reference><Reference><Citation>Filippi CM, von Herrath MG. 2008. Viral trigger for type 1 diabetes: pros and cons. Diabetes 57:2863–2871. doi:10.2337/db07-1023</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db07-1023</ArticleId><ArticleId IdType="pmc">PMC2570378</ArticleId><ArticleId IdType="pubmed">18971433</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JJ, Jabri B, Dermody TS. 2018. A viral trigger for celiac disease. PLoS Pathog 14:e1007181. doi:10.1371/journal.ppat.1007181</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007181</ArticleId><ArticleId IdType="pmc">PMC6147651</ArticleId><ArticleId IdType="pubmed">30235320</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra AK, Clarke K. 2010. Viral obesity: fact or fiction? Obes Rev 11:289–296. doi:10.1111/j.1467-789X.2009.00677.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-789X.2009.00677.x</ArticleId><ArticleId IdType="pubmed">19874530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung H-P, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. 2020. Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol Med 26:296–310. doi:10.1016/j.molmed.2019.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2019.11.003</ArticleId><ArticleId IdType="pmc">PMC7106557</ArticleId><ArticleId IdType="pubmed">31862243</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, Elledge SJ, Niebuhr DW, Scher AI, Munger KL, Ascherio A. 2022. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375:296–301. doi:10.1126/science.abj8222</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId><ArticleId IdType="pubmed">35025605</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarid R, Gao S-J. 2011. Viruses and human cancer: from detection to causality. Cancer Lett 305:218–227. doi:10.1016/j.canlet.2010.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2010.09.011</ArticleId><ArticleId IdType="pmc">PMC3037427</ArticleId><ArticleId IdType="pubmed">20971551</ArticleId></ArticleIdList></Reference><Reference><Citation>Devanand DP. 2018. Viral hypothesis and antiviral treatment in Alzheimer’s disease. Curr Neurol Neurosci Rep 18:55. doi:10.1007/s11910-018-0863-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-018-0863-1</ArticleId><ArticleId IdType="pmc">PMC6450072</ArticleId><ArticleId IdType="pubmed">30008124</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Markowitz LE, Hariri S, Panicker G, Unger ER. 2016. Seroprevalence of 9 human papillomavirus types in the United States, 2005-2006. J Infect Dis 213:191–198. doi:10.1093/infdis/jiv403</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiv403</ArticleId><ArticleId IdType="pmc">PMC11357742</ArticleId><ArticleId IdType="pubmed">26320259</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964–973. doi:10.1001/jama.296.8.964</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.296.8.964</ArticleId><ArticleId IdType="pubmed">16926356</ArticleId></ArticleIdList></Reference><Reference><Citation>
CDC . 2021. HIV and gay and bisexual men. Available from: https://www.cdc.gov/hiv/group/msm/index.html. Retrieved
15 Aug 2022.</Citation></Reference><Reference><Citation>Purcell DW, Johnson CH, Lansky A, Prejean J, Stein R, Denning P, Gau Z, Weinstock H, Su J, Crepaz N. 2012. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS J 6:98–107. doi:10.2174/1874613601206010098</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874613601206010098</ArticleId><ArticleId IdType="pmc">PMC3462414</ArticleId><ArticleId IdType="pubmed">23049658</ArticleId></ArticleIdList></Reference><Reference><Citation>Erhart LM, Ernst KC. 2012. The changing epidemiology of hepatitis A in Arizona following intensive immunization programs (1988-2007). Vaccine 30:6103–6110. doi:10.1016/j.vaccine.2012.07.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.07.029</ArticleId><ArticleId IdType="pubmed">22835739</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . 2009. Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization</Citation><ArticleIdList><ArticleId IdType="pubmed">23762963</ArticleId></ArticleIdList></Reference><Reference><Citation>
Statistics and maps - 2020. 2022. Available from: https://www.cdc.gov/dengue/statistics-maps/2020.html. Retrieved
23 Aug 2022.</Citation></Reference><Reference><Citation>Hans R, Marwaha N. 2014. Nucleic acid testing-benefits and constraints. Asian J Transfus Sci 8:2–3. doi:10.4103/0973-6247.126679</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0973-6247.126679</ArticleId><ArticleId IdType="pmc">PMC3943139</ArticleId><ArticleId IdType="pubmed">24678164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lequin RM. 2005. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem 51:2415–2418. doi:10.1373/clinchem.2005.051532</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2005.051532</ArticleId><ArticleId IdType="pubmed">16179424</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung’u T, Ruxrungtham K, Sanchez J, Brander C, Chung RT, O’Connor KC, Walker B, Larman HB, Elledge SJ. 2015. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 348:aaa0698. doi:10.1126/science.aaa0698</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa0698</ArticleId><ArticleId IdType="pmc">PMC4844011</ArticleId><ArticleId IdType="pubmed">26045439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladner JT, Henson SN, Boyle AS, Engelbrektson AL, Fink ZW, Rahee F, D’ambrozio J, Schaecher KE, Stone M, Dong W, Dadwal S, Yu J, Caligiuri MA, Cieplak P, Bjørås M, Fenstad MH, Nordbø SA, Kainov DE, Muranaka N, Chee MS, Shiryaev SA, Altin JA. 2021. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med 2:100189. doi:10.1016/j.xcrm.2020.100189</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100189</ArticleId><ArticleId IdType="pmc">PMC7816965</ArticleId><ArticleId IdType="pubmed">33495758</ArticleId></ArticleIdList></Reference><Reference><Citation>Elko EA, Nelson GA, Mead HL, Kelley EJ, Carvalho ST, Sarbo NG, Harms CE, Le Verche V, Cardoso AA, Ely JL, Boyle AS, Piña A, Henson SN, Rahee F, Keim PS, Celona KR, Yi J, Settles EW, Bota DA, Yu GC, Morris SR, Zaia JA, Ladner JT, Altin JA. 2022. COVID-19 vaccination elicits an evolving, cross-reactive antibody response to epitopes conserved with endemic coronavirus spike proteins. Cell Rep 40:111022. doi:10.1016/j.celrep.2022.111022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111022</ArticleId><ArticleId IdType="pmc">PMC9188999</ArticleId><ArticleId IdType="pubmed">35753310</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley EJ, Henson SN, Rahee F, Boyle AS, Engelbrektson AL, Nelson GA, Mead HL, Anderson NL, Razavi M, Yip R, Ladner JT, Scriba TJ, Altin JA. 2023. Virome-wide detection of natural infection events and the associated antibody dynamics using longitudinal highly-multiplexed serology. Nat Commun 14:1783. doi:10.1038/s41467-023-37378-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37378-z</ArticleId><ArticleId IdType="pmc">PMC10062260</ArticleId><ArticleId IdType="pubmed">36997517</ArticleId></ArticleIdList></Reference><Reference><Citation>Elko EA, Mead HL, Nelson GA, Zaia JA, Ladner JT, Altin JA. 2024. Recurrent SARS-CoV-2 mutations at Spike D796 evade antibodies from pre-Omicron convalescent and vaccinated subjects. Microbiol Spectr 12:e0329123. doi:10.1128/spectrum.03291-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.03291-23</ArticleId><ArticleId IdType="pmc">PMC10871546</ArticleId><ArticleId IdType="pubmed">38189279</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson SN, Elko EA, Swiderski PM, Liang Y, Engelbrektson AL, Piña A, Boyle AS, Fink Z, Facista SJ, Martinez V, Rahee F, Brown A, Kelley EJ, Nelson GA, Raspet I, Mead HL, Altin JA, Ladner JT. 2023. PepSeq: a fully in vitro platform for highly multiplexed serology using customizable DNA-barcoded peptide libraries. Nat Protoc 18:396–423. doi:10.1038/s41596-022-00766-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-022-00766-8</ArticleId><ArticleId IdType="pmc">PMC10339795</ArticleId><ArticleId IdType="pubmed">36385198</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan D, Wansley DL, Sie BM, Noon MS, Baer AN, Laserson U, Larman HB. 2018. PhIP-Seq characterization of serum antibodies using oligonucleotide-encoded peptidomes. Nat Protoc 13:1958–1978. doi:10.1038/s41596-018-0025-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0025-6</ArticleId><ArticleId IdType="pmc">PMC6568263</ArticleId><ArticleId IdType="pubmed">30190553</ArticleId></ArticleIdList></Reference><Reference><Citation>Patricia O’Campo JB. 2004. Eliminating health disparities: measurement and data needs. National Academies Press.</Citation><ArticleIdList><ArticleId IdType="pubmed">25009872</ArticleId></ArticleIdList></Reference><Reference><Citation>Staras SAS, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. 2006. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43:1143–1151. doi:10.1086/508173</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/508173</ArticleId><ArticleId IdType="pubmed">17029132</ArticleId></ArticleIdList></Reference><Reference><Citation>Balfour HH, Sifakis F, Sliman JA, Knight JA, Schmeling DO, Thomas W. 2013. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis 208:1286–1293. doi:10.1093/infdis/jit321</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit321</ArticleId><ArticleId IdType="pubmed">23868878</ArticleId></ArticleIdList></Reference><Reference><Citation>Klevens RM, Kruszon-Moran D, Wasley A, Gallagher K, McQuillan GM, Kuhnert W, Teshale EH, Drobeniuc J, Bell BP. 2011. Seroprevalence of hepatitis A virus antibodies in the U.S.: results from the national health and nutrition examination survey. Public Health Rep 126:522–532. doi:10.1177/003335491112600408</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/003335491112600408</ArticleId><ArticleId IdType="pmc">PMC3115211</ArticleId><ArticleId IdType="pubmed">21800746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell BP, Kruszon-Moran D, Shapiro CN, Lambert SB, McQuillan GM, Margolis HS. 2005. Hepatitis A virus infection in the United States: serologic results from the third national health and nutrition examination survey. Vaccine 23:5798–5806. doi:10.1016/j.vaccine.2005.03.060</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.03.060</ArticleId><ArticleId IdType="pubmed">16307834</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kington RS. 2004. Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health 94:1952–1958. doi:10.2105/ajph.94.11.1952</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.94.11.1952</ArticleId><ArticleId IdType="pmc">PMC1448568</ArticleId><ArticleId IdType="pubmed">15514236</ArticleId></ArticleIdList></Reference><Reference><Citation>Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562. doi:10.1056/NEJM199908193410802</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199908193410802</ArticleId><ArticleId IdType="pubmed">10451460</ArticleId></ArticleIdList></Reference><Reference><Citation>Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, Takahashi M, Baba K. 1989. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 27:651–653. doi:10.1128/jcm.27.4.651-653.1989</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.27.4.651-653.1989</ArticleId><ArticleId IdType="pmc">PMC267390</ArticleId><ArticleId IdType="pubmed">2542358</ArticleId></ArticleIdList></Reference><Reference><Citation>Engels EA, Atkinson JO, Graubard BI, McQuillan GM, Gamache C, Mbisa G, Cohn S, Whitby D, Goedert JJ. 2007. Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission. J Infect Dis 196:199–207. doi:10.1086/518791</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/518791</ArticleId><ArticleId IdType="pubmed">17570106</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis Mes, Rauch KJ, Petersen LR, Anderson JE, Schable CA, Dondero TJ. 1990. Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States. The sentinel hospital surveillance group. N Engl J Med 323:213–218. doi:10.1056/NEJM199007263230401</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199007263230401</ArticleId><ArticleId IdType="pubmed">2366832</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. 2009. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: national health and nutrition examination survey 2003-2004. J Infect Dis 200:1059–1067. doi:10.1086/604729</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/604729</ArticleId><ArticleId IdType="pubmed">19719390</ArticleId></ArticleIdList></Reference><Reference><Citation>Schillinger JA, Xu F, Sternberg MR, Armstrong GL, Lee FK, Nahmias AJ, McQuillan GM, Louis ME, Markowitz LE. 2004. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis 31:753–760. doi:10.1097/01.olq.0000145852.43262.c3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.olq.0000145852.43262.c3</ArticleId><ArticleId IdType="pubmed">15608591</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuillan G, Kruszon-Moran D, Flagg EW, Paulose-Ram R. 2018. Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016. NCHS Data Brief:1–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29442994</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK, St Louis ME. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 337:1105–1111. doi:10.1056/NEJM199710163371601</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199710163371601</ArticleId><ArticleId IdType="pubmed">9329932</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) . 2010. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep 59:456–459.</Citation><ArticleIdList><ArticleId IdType="pubmed">20414188</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. 1999. Prevalence of hepatitis B virus infection in the United States: the national health and nutrition examination surveys, 1976 through 1994. Am J Public Health 89:14–18. doi:10.2105/ajph.89.1.14</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.89.1.14</ArticleId><ArticleId IdType="pmc">PMC1508496</ArticleId><ArticleId IdType="pubmed">9987458</ArticleId></ArticleIdList></Reference><Reference><Citation>Teshale EH, Denniston MM, Drobeniuc J, Kamili S, Teo C-G, Holmberg SD. 2015. Decline in hepatitis E virus antibody prevalence in the United States from 1988-1994 to 2009-2010. J Infect Dis 211:366–373. doi:10.1093/infdis/jiu466</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu466</ArticleId><ArticleId IdType="pubmed">25147277</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. 2009. Epidemiology of hepatitis E virus in the United States: results from the third national health and nutrition examination survey, 1988-1994. J Infect Dis 200:48–56. doi:10.1086/599319</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/599319</ArticleId><ArticleId IdType="pmc">PMC2762746</ArticleId><ArticleId IdType="pubmed">19473098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebo EJ, Kruszon-Moran DM, Marin M, Bellini WJ, Schmid S, Bialek SR, Wallace GS, McLean HQ. 2015. Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009-2010. Open Forum Infect Dis 2:fv006. doi:10.1093/ofid/ofv006</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofv006</ArticleId><ArticleId IdType="pmc">PMC4438887</ArticleId><ArticleId IdType="pubmed">26034757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchins SS, Bellini WJ, Coronado V, Jiles R, Wooten K, Deladisma A. 2004. Population immunity to measles in the United States, 1999. J Infect Dis 189 Suppl 1:S91–S97. doi:10.1086/377713</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/377713</ArticleId><ArticleId IdType="pubmed">15106096</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby AE, Kienast Y, Zhu W, Barton J, Anderson E, Sizemore M, Vinje J, Moe CL. 2020. Norovirus seroprevalence among adults In the United States: analysis of NHANES serum specimens from 1999-2000 and 2003-2004. Viruses 12:179. doi:10.3390/v12020179</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12020179</ArticleId><ArticleId IdType="pmc">PMC7077181</ArticleId><ArticleId IdType="pubmed">32033378</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisano MB, Campbell C, Anugwom C, Ré VE, Debes JD. 2022. Hepatitis E virus infection in the United States: seroprevalence, risk factors and the influence of immunological assays. PLoS One 17:e0272809. doi:10.1371/journal.pone.0272809</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272809</ArticleId><ArticleId IdType="pmc">PMC9355204</ArticleId><ArticleId IdType="pubmed">35930611</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahill ME, Yao Y, Nock D, Armstrong PM, Andreadis TG, Diuk-Wasser MA, Montgomery RR. 2017. West Nile virus seroprevalence, Connecticut, USA, 2000-2014. Emerg Infect Dis 23:708–710. doi:10.3201/eid2304.161669</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2304.161669</ArticleId><ArticleId IdType="pmc">PMC5367428</ArticleId><ArticleId IdType="pubmed">28322715</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweitzer BK, Kramer WL, Sambol AR, Meza JL, Hinrichs SH, Iwen PC. 2006. Geographic factors contributing to a high seroprevalence of West Nile virus-specific antibodies in humans following an epidemic. Clin Vaccine Immunol 13:314–318. doi:10.1128/CVI.13.3.314-318.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.13.3.314-318.2006</ArticleId><ArticleId IdType="pmc">PMC1391969</ArticleId><ArticleId IdType="pubmed">16522771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Luo J, Wang X, Xi J, Pan Y, Chen J, Yang X, Li G, Sun Q, Yang J. 2017. Development of A peptide ELISA to discriminate vaccine-induced immunity from natural infection of hepatitis A virus in A phase IV study. Eur J Clin Microbiol Infect Dis 36:2165–2170. doi:10.1007/s10096-017-3040-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-017-3040-6</ArticleId><ArticleId IdType="pubmed">28631170</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro-Murillo JA, Ávila-Agüero ML, Fitzpatrick MC, Crystal CJ, Falleiros-Arlant L-H, Galvani AP. 2020. The case for replacing live oral polio vaccine with inactivated vaccine in the Americas. Lancet 395:1163–1166. doi:10.1016/S0140-6736(20)30213-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30213-0</ArticleId><ArticleId IdType="pmc">PMC8572547</ArticleId><ArticleId IdType="pubmed">32247397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang X, Li Y, Fan L, Lin F, Wei J, Zhu X, Hu Y, Li J, Chang G, Zhu Q, Liu H, Yang Y. 2012. Development of an ELISA-array for simultaneous detection of five encephalitis viruses. Virol J 9:56. doi:10.1186/1743-422X-9-56</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-56</ArticleId><ArticleId IdType="pmc">PMC3305475</ArticleId><ArticleId IdType="pubmed">22369052</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushi S. 2020. Competitive ELISA for the detection of serum antibodies specific for middle east respiratory syndrome coronavirus (MERS-CoV). Methods Mol Biol 2203:55–65. doi:10.1007/978-1-0716-0900-2_4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0900-2_4</ArticleId><ArticleId IdType="pubmed">32833203</ArticleId></ArticleIdList></Reference><Reference><Citation>Cangin C, Focht B, Harris R, Strunk JA. 2019. Hepatitis E seroprevalence in the United States: results for immunoglobulins IGG and IGM. J Med Virol 91:124–131. doi:10.1002/jmv.25299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25299</ArticleId><ArticleId IdType="pubmed">30168589</ArticleId></ArticleIdList></Reference><Reference><Citation>Boncristiani HF, Criado MF, Arruda E. 2009. Respiratory viruses, p 500–518. In Encyclopedia of microbiology. Elsevier.</Citation></Reference><Reference><Citation>Dunn SR, Ryder AB, Tollefson SJ, Xu M, Saville BR, Williams JV. 2013. Seroepidemiologies of human metapneumovirus and respiratory syncytial virus in young children, determined with a new recombinant fusion protein enzyme-linked immunosorbent assay. Clin Vaccine Immunol 20:1654–1656. doi:10.1128/CVI.00750-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00750-12</ArticleId><ArticleId IdType="pmc">PMC3807191</ArticleId><ArticleId IdType="pubmed">23945161</ArticleId></ArticleIdList></Reference><Reference><Citation>Parrott RH, Vargosko AJ, Bell JA, Chanock RM. 1962. Acute respiratory diseases of viral etiology. III. parainfluenza. Myxoviruses. Am J Public Health Nations Health 52:907–917. doi:10.2105/ajph.52.6.907</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.52.6.907</ArticleId><ArticleId IdType="pmc">PMC1523067</ArticleId><ArticleId IdType="pubmed">14038204</ArticleId></ArticleIdList></Reference><Reference><Citation>DeGroote NP, Haynes AK, Taylor C, Killerby ME, Dahl RM, Mustaquim D, Gerber SI, Watson JT. 2020. Human parainfluenza virus circulation, United States, 2011-2019. J Clin Virol 124:104261. doi:10.1016/j.jcv.2020.104261</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104261</ArticleId><ArticleId IdType="pmc">PMC7106518</ArticleId><ArticleId IdType="pubmed">31954277</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone O, Meissner HC. 2020. The importance of MMR immunization in the United States. Pediatrics 146:e20200251. doi:10.1542/peds.2020-0251</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-0251</ArticleId><ArticleId IdType="pubmed">32719087</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker-Dreps S, González F, Bucardo F. 2020. Sapovirus: an emerging cause of childhood diarrhea. Curr Opin Infect Dis 33:388–397. doi:10.1097/QCO.0000000000000671</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000671</ArticleId><ArticleId IdType="pmc">PMC7748384</ArticleId><ArticleId IdType="pubmed">32796163</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubicz R, Leach CT, Kraig E, Dhurandhar NV, Grubbs B, Blangero J, Yolken R, Göring HH. 2011. Seroprevalence of 13 common pathogens in a rapidly growing U.S. minority population: Mexican Americans from San Antonio, TX. BMC Res Notes 4:433. doi:10.1186/1756-0500-4-433</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-4-433</ArticleId><ArticleId IdType="pmc">PMC3214184</ArticleId><ArticleId IdType="pubmed">22018212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst KC, Erhart LM. 2014. The role of ethnicity and travel on hepatitis A vaccination coverage and disease incidence in Arizona at the United States-Mexico Border. Hum Vaccin Immunother 10:1396–1403. doi:10.4161/hv.28140</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.28140</ArticleId><ArticleId IdType="pmc">PMC4896613</ArticleId><ArticleId IdType="pubmed">24603091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazcano-Ponce E, Conde-Gonzalez C, Rojas R, DeAntonio R, Romano-Mazzotti L, Cervantes Y, Ortega-Barria E. 2013. Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico: implications for hepatitis A vaccination. Hum Vaccin Immunother 9:375–381. doi:10.4161/hv.22774</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.22774</ArticleId><ArticleId IdType="pmc">PMC3859760</ArticleId><ArticleId IdType="pubmed">23291940</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Victoria J, Kapoor A, Blinkova O, Wang C, Babrzadeh F, Mason CJ, Pandey P, Triki H, Bahri O, Oderinde BS, Baba MM, Bukbuk DN, Besser JM, Bartkus JM, Delwart EL. 2009. A novel picornavirus associated with gastroenteritis. J Virol 83:12002–12006. doi:10.1128/JVI.01241-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01241-09</ArticleId><ArticleId IdType="pmc">PMC2772710</ArticleId><ArticleId IdType="pubmed">19759142</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitajima M, Iker BC, Rachmadi AT, Haramoto E, Gerba CP. 2014. Quantification and genetic analysis of salivirus/klassevirus in wastewater in Arizona, USA. Food Environ Virol 6:213–216. doi:10.1007/s12560-014-9148-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12560-014-9148-2</ArticleId><ArticleId IdType="pubmed">24863500</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauly M, Hoppe E, Mugisha L, Petrzelkova K, Akoua-Koffi C, Couacy-Hymann E, Anoh AE, Mossoun A, Schubert G, Wiersma L, Pascale S, Muyembe J-J, Karhemere S, Weiss S, Leendertz SA, Calvignac-Spencer S, Leendertz FH, Ehlers B. 2014. High prevalence and diversity of species D adenoviruses (HAdV-D) in human populations of four Sub-Saharan countries. Virol J 11:25. doi:10.1186/1743-422X-11-25</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-11-25</ArticleId><ArticleId IdType="pmc">PMC3928611</ArticleId><ArticleId IdType="pubmed">24512686</ArticleId></ArticleIdList></Reference><Reference><Citation>Karelehto E, Brouwer L, Benschop K, Kok J, Basile K, McMullan B, Rawlinson W, Druce J, Nicholson S, Selvarangan R, Harrison C, Lankachandra K, van Eijk H, Koen G, de Jong M, Pajkrt D, Wolthers KC. 2019. Seroepidemiology of parechovirus A3 neutralizing antibodies, Australia, the Netherlands, and United States. Emerg Infect Dis 25:148–152. doi:10.3201/eid2501.180352</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2501.180352</ArticleId><ArticleId IdType="pmc">PMC6302606</ArticleId><ArticleId IdType="pubmed">30561318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridhar A, Karelehto E, Brouwer L, Pajkrt D, Wolthers KC. 2019. Parechovirus A pathogenesis and the enigma of genotype A-3. Viruses 11:1062. doi:10.3390/v11111062</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11111062</ArticleId><ArticleId IdType="pmc">PMC6893760</ArticleId><ArticleId IdType="pubmed">31739613</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver S, James SH. 2017. Herpesviruses, p 621–627. In International encyclopedia of public health. Elsevier.</Citation></Reference><Reference><Citation>Epstein LG, Shinnar S, Hesdorffer DC, Nordli DR, Hamidullah A, Benn EKT, Pellock JM, Frank LM, Lewis DV, Moshe SL, Shinnar RC, Sun S, FEBSTAT study team . 2012. Human herpesvirus 6 and 7 in febrile status epilepticus: the FEBSTAT study. Epilepsia 53:1481–1488. doi:10.1111/j.1528-1167.2012.03542.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2012.03542.x</ArticleId><ArticleId IdType="pmc">PMC3442944</ArticleId><ArticleId IdType="pubmed">22954016</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Qu T, Li D, Jing J, Deng Q, Wan X. 2022. Human herpesvirus 7 encephalitis in an immunocompetent adult and a literature review. Virol J 19:200. doi:10.1186/s12985-022-01925-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01925-9</ArticleId><ArticleId IdType="pmc">PMC9707246</ArticleId><ArticleId IdType="pubmed">36447267</ArticleId></ArticleIdList></Reference><Reference><Citation>Immigrants in Arizona. 2020. American Immigration Council.</Citation></Reference><Reference><Citation>Wald A, Corey L. 2007. Persistence in the population: epidemiology, transmission. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge.</Citation><ArticleIdList><ArticleId IdType="pubmed">21348071</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao G, Jing W, Liu J, Liu M. 2021. The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention. Hepatol Int 15:1068–1082. doi:10.1007/s12072-021-10232-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-021-10232-4</ArticleId><ArticleId IdType="pmc">PMC8514357</ArticleId><ArticleId IdType="pubmed">34345993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. 2019. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol 29:e2034. doi:10.1002/rmv.2034</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2034</ArticleId><ArticleId IdType="pubmed">30706584</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti MV, Razonable RR. 2016. Cytomegalovirus. Microbiol Spectr 4. doi:10.1128/microbiolspec.DMIH2-0022-2015</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/microbiolspec.DMIH2-0022-2015</ArticleId><ArticleId IdType="pubmed">27726793</ArticleId></ArticleIdList></Reference><Reference><Citation>Verbeek R, Vandekerckhove L, Van Cleemput J. 2024. Update on human herpesvirus 7 pathogenesis and clinical aspects as a roadmap for future research. J Virol 98:e0043724. doi:10.1128/jvi.00437-24</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00437-24</ArticleId><ArticleId IdType="pmc">PMC11237674</ArticleId><ArticleId IdType="pubmed">38717112</ArticleId></ArticleIdList></Reference><Reference><Citation>Arduino PG, Porter SR. 2008. Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med 37:107–121. doi:10.1111/j.1600-0714.2007.00586.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0714.2007.00586.x</ArticleId><ArticleId IdType="pubmed">18197856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintó RM, Pérez-Rodríguez F-J, Costafreda M-I, Chavarria-Miró G, Guix S, Ribes E, Bosch A. 2021. Pathogenicity and virulence of hepatitis A virus. Virulence 12:1174–1185. doi:10.1080/21505594.2021.1910442</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2021.1910442</ArticleId><ArticleId IdType="pmc">PMC8043188</ArticleId><ArticleId IdType="pubmed">33843464</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero JR, Selvarangan R. 2011. The human parechoviruses: an overview. Adv Pediatr 58:65–85. doi:10.1016/j.yapd.2011.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yapd.2011.03.008</ArticleId><ArticleId IdType="pubmed">21736976</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter G, Pankovics P, Boros Á. 2017. Saliviruses-the first knowledge about a newly discovered human picornavirus. Rev Med Virol 27:27. doi:10.1002/rmv.1904</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1904</ArticleId><ArticleId IdType="pubmed">27641729</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson CM, Seto D, Jones MS, Dyer DW, Chodosh J. 2011. Molecular evolution of human species D adenoviruses. Infect Genet Evol 11:1208–1217. doi:10.1016/j.meegid.2011.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2011.04.031</ArticleId><ArticleId IdType="pmc">PMC3139803</ArticleId><ArticleId IdType="pubmed">21570490</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson BH, Jia XY, Tian H, Margolis HS, Summers DF, Ehrenfeld E. 1992. Serological approaches to distinguish immune response to hepatitis A vaccine and natural infection. Vaccine 10 Suppl 1:S106–S109. doi:10.1016/0264-410x(92)90559-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410x(92)90559-3</ArticleId><ArticleId IdType="pubmed">1335637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokarz R, Haq S, Sameroff S, Howie SRC, Lipkin WI. 2013. Genomic analysis of coxsackieviruses A1, A19, A22, enteroviruses 113 and 104: viruses representing two clades with distinct tropism within enterovirus C. J Gen Virol 94:1995–2004. doi:10.1099/vir.0.053462-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.053462-0</ArticleId><ArticleId IdType="pmc">PMC3749054</ArticleId><ArticleId IdType="pubmed">23761409</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer L, Benschop KSM, Nguyen D, Kamau E, Pajkrt D, Simmonds P, Wolthers KC. 2020. Recombination analysis of non-poliovirus members of the enterovirus C species; restriction of recombination events to members of the same 3DPol cluster. Viruses 12:706. doi:10.3390/v12070706</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12070706</ArticleId><ArticleId IdType="pmc">PMC7412211</ArticleId><ArticleId IdType="pubmed">32629843</ArticleId></ArticleIdList></Reference><Reference><Citation>Basit H, Tyagi I, Koirala J. 2023. Hepatitis CStatPearls. StatPearls Publishing, Treasure Island (FL).</Citation><ArticleIdList><ArticleId IdType="pubmed">28613647</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG, Overbaugh J, Phillips A, Buchbinder S. 2015. HIV infection. Nat Rev Dis Primers 1:15035. doi:10.1038/nrdp.2015.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.35</ArticleId><ArticleId IdType="pubmed">27188527</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink ZW, Martinez V, Altin J, Ladner JT. 2020. PepSIRF: a flexible and comprehensive tool for the analysis of data from highly-multiplexed DNA-barcoded peptide assays. arXiv:2007.</Citation></Reference><Reference><Citation>Brown AM, Bolyen E, Raspet I, Altin JA, Ladner JT. 2022. PepSIRF + QIIME 2: software tools for automated, reproducible analysis of highly-multiplexed serology data. 10.48550/ARXIV.2207.11509.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/ARXIV.2207.11509</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, Siljander H, Rewers M, Choy DF, Wilson MS, Larman HB, Nelson AN, Griffin DE, de Swart RL, Elledge SJ. 2019. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science 366:599–606. doi:10.1126/science.aay6485</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay6485</ArticleId><ArticleId IdType="pmc">PMC8590458</ArticleId><ArticleId IdType="pubmed">31672891</ArticleId></ArticleIdList></Reference><Reference><Citation>Seabold S, Perktold J. 2010. Statsmodels: econometric and statistical modeling with Python. Python in Science Conference; Austin, Texas. SciPy. doi:10.25080/Majora-92bf1922-011</Citation><ArticleIdList><ArticleId IdType="doi">10.25080/Majora-92bf1922-011</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 30:772–780. doi:10.1093/molbev/mst010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/mst010</ArticleId><ArticleId IdType="pmc">PMC3603318</ArticleId><ArticleId IdType="pubmed">23329690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. 2019. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. Bioinformatics 35:4453–4455. doi:10.1093/bioinformatics/btz305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btz305</ArticleId><ArticleId IdType="pmc">PMC6821337</ArticleId><ArticleId IdType="pubmed">31070718</ArticleId></ArticleIdList></Reference><Reference><Citation>Keane TM, Creevey CJ, Pentony MM, Naughton TJ, Mclnerney JO. 2006. Assessment of methods for amino acid matrix selection and their use on empirical data shows that ad hoc assumptions for choice of matrix are not justified. BMC Evol Biol 6:29. doi:10.1186/1471-2148-6-29</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2148-6-29</ArticleId><ArticleId IdType="pmc">PMC1435933</ArticleId><ArticleId IdType="pubmed">16563161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>